
DYMDF
US listing
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 31, 2021 | Time not confirmed | 0.00 | -0.04 | — |
| May 31, 2021 | Time not confirmed | 0.00 | -0.06 | — |
| Feb 28, 2021 | Time not confirmed | 0.00 | 0.03 | — |
| Nov 30, 2020 | Time not confirmed | 0.00 | 0.18 | — |
| Aug 31, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| May 31, 2020 | Time not confirmed | 0.00 | -0.01 | — |
| Feb 29, 2020 | Time not confirmed | 0.00 | 0.06 | — |
| Nov 30, 2019 | Time not confirmed | 0.00 | -0.01 | — |
| Aug 31, 2019 | Time not confirmed | 0.00 | -0.01 | — |
| May 31, 2019 | Time not confirmed | 0.00 | -0.01 | — |
| Feb 28, 2019 | Time not confirmed | 0.00 | -0.02 | — |
| Nov 30, 2018 | Time not confirmed | 0.00 | -0.02 | — |
| Aug 31, 2018 | Time not confirmed | 0.00 | -0.02 | — |
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and…
| Time not confirmed |
| 0.00 |
| -0.03 |
| — |
| Feb 28, 2018 | Time not confirmed | 0.00 | -0.02 | — |